by Ed Susman: For More Info, Go Here…
When treated with tezepelumab, an investigational asthma drug with a novel mechanism, patients showed significant reductions in hospital admissions and visits to the emergency room, according to a new analysis of the phase IIb PATHWAY trial reported here.
In an exploratory analysis, exacerbations requiring hospitalization were reduced 79% overall if the patients were on any dose of tezepelumab when compared to placebo, said Jonathon Corren, MD, of UCLA Medical Center in Los Angeles and UCLA Medical Center-Santa Monica in California.
Similarly, overall hospitalizations were reduced by 61% among patients on tezepelumab; all-cause emergency room visits were reduced by 60%. The percentage of patients who went to the emergency room with asthma exacerbation was 3.6% among the placebo patients and 1.2% among those on tezepelumab.
The mean number of days placebo patients spend in the hospital per admission was 23 compared with 9 for patients on tezepelumab (P<0.05), Corren said.
“These data provide further evidence that blocking TSLP is an effective strategy for the treatment of severe, uncontrolled asthma,” he said.